Washing the application site two hours after applying removes over 80% of the testosterone that could transfer to someone else. That single fact reframes most of what’s written about gel, which tends to treat transference as an unmanageable hazard rather than a time-limited, controllable one.
The two concerns worth your attention with gel are transference and absorption variability, both real, both manageable once you understand the specifics.
This article gives you the specific version: how careful you actually need to be about transference, why your levels might not reflect your dose, and what to do about each.
Testosterone Gel Transference: What the Risk Is and What Precaution Is Sufficient
Every article on gel mentions transference (the unintended transfer of testosterone from your skin to someone else’s through direct contact). Almost none answer the question you actually have: how careful do I need to be, specifically?
Here’s what the data shows.
The risk is real but time-limited. In the FDA clinical study underpinning AndroGel’s labeling, couples engaged in 15 minutes of vigorous skin-to-skin contact two hours after the man applied gel to his arm and shoulder. The female partners showed meaningfully elevated testosterone.
But a separate set of studies found that washing the application site with soap and water just two hours after applying removed at least 81% of the residual testosterone from the skin, and brought partner exposure essentially back to baseline (Stahlman et al., Current Medical Research and Opinion 2012). Covering the site with a t-shirt alone substantially reduced transfer.
So the risk isn’t a vague, permanent cloud. It’s concentrated in the first few hours, on bare, unwashed skin, with direct contact.
What Exposure Actually Does, and It Depends Who Is Exposed
The consequences are not the same for every person who might come into contact with the application site:
- Adult female partner: Prolonged, repeated exposure can cause virilization (the development of male-pattern characteristics, acne, increased body or facial hair, voice changes, and in significant exposures, clitoral enlargement). The key word is repeated. A single incidental brush of contact does not cause this. The risk is cumulative, built from regular direct contact over time, not from one accidental touch.
- Children: Considerably more sensitive. Documented cases describe young children developing premature pubic hair, genital enlargement, and behavioral changes after secondary exposure. The FDA’s boxed warning on topical testosterone exists largely because of pediatric cases, children represented a substantial share of reported secondary-exposure incidents (Stahlman et al., 2012). With children, even single exposures can matter, which is why their precaution threshold is stricter than for an adult partner.
- Pregnant partner: This is the highest-risk scenario. Testosterone is a teratogen (a substance that can cause birth defects), and exposure of a female fetus to androgens can cause varying degrees of virilization. Topical testosterone is formally contraindicated around pregnancy. This isn’t a “be careful” situation, it’s a “strict avoidance of any contact with application sites” situation.
The Four Steps That Actually Eliminate Meaningful Risk
The precaution that works isn’t “avoid skin contact”, that instruction is useless because it doesn’t tell you for how long or under what conditions. The specific, evidence-based protocol is:
- Apply at a consistent time daily: Morning works well because it maximizes the gap before close evening contact.
- Cover the application site with clothing: Once the gel has dried (a shirt is sufficient for shoulder/arm application).
- Wash your hands immediately with soap and water after applying.
- If close contact before four hours is unavoidable, shower and wash the site first, this removes the large majority of transferable residue.
A man who follows these four steps has effectively eliminated meaningful transfer risk under normal household conditions. The reason competitor articles don’t give you this is that “avoid skin contact” is easier to write than the actual protocol. But it leaves you unable to act, which is worse than no advice.
Absorption Variability: Why Your Levels May Not Reflect Your Dose
This is the most underexplained problem with gel, and it’s the reason a lot of men conclude “gel doesn’t work for me” when the real issue is something specific and fixable.
Topical absorption is genuinely variable between individuals. Skin thickness, body fat percentage, where you apply it, and whether the skin is clean and dry all affect how much testosterone actually reaches your bloodstream.
The difference isn’t trivial, in pharmacokinetic studies, applying gel to the abdomen produced 30–40% lower bioavailability (the proportion of the dose that actually reaches circulation) than applying the same dose to the upper arms and shoulders (Endocrine Practice 2011).
Two men on an identical prescription can end up with serum testosterone levels (the amount measured in your blood) that differ substantially.
This is physiology, not non-compliance. If your levels are low at follow-up, the default assumption is often that you skipped doses or applied incorrectly. Frequently, you did everything right and simply absorb poorly.
What Poor Absorption Looks Like, and What to Do About It
The clinical picture: You’ve used the gel exactly as prescribed every day, and at 8 weeks your testosterone is still low-normal or below range. The response options, in order:
- Increase the dose, the simplest first step
- Switch to a higher-concentration formulation, same testosterone, less gel volume, sometimes better absorption
- Switch to scrotal application, the option most patients have never heard of
Scrotal application deserves its own explanation, because it’s the single most actionable thing a poor absorber can take to their clinic. Scrotal skin is unusually thin and highly permeable to steroids.
A controlled pharmacokinetic study found that testosterone cream applied to scrotal skin produced therapeutic blood levels at substantially lower doses than non-scrotal skin requires, the bioavailability via scrotal skin is “strikingly higher” than the conventional arm or shoulder route (Iyer et al., Andrology 2017). Some protocols use this deliberately for men who don’t reach target on standard application.
The tradeoff: Scrotal application tends to produce higher DHT (dihydrotestosterone, a more potent androgen your body converts testosterone into) than other sites, which matters if you’re prone to DHT-driven effects like hair loss. It’s a clinic conversation, not a self-experiment, but it’s a specific, evidence-based option that most patients are never told exists.
Testosterone Gel Skin Reactions: What It Is and What to Do
Most gel skin reactions are mild and fixable. Here’s how to tell which tier yours is.
| Tier | What it looks like | What to do |
| Tier 1: Self-resolving | Mild redness or dryness at the site, common with high-alcohol gels like AndroGel | Rotate application sites; apply to dry skin after showering to reduce alcohol irritation. No clinic call needed. |
| Tier 2: Needs adjustment | Persistent itching, rash, or irritation not resolving after two weeks of site rotation | Likely a formulation sensitivity, not a testosterone sensitivity. Switching to a lower-alcohol cream or different site usually resolves it. |
| Tier 3: Contact your clinic | Hives, significant swelling, or difficulty breathing after application | Allergic reaction. Stop application and seek medical review promptly. |
The distinction in Tier 2 matters: most men who react to a gel are reacting to the alcohol carrier, not the testosterone itself. That’s why a formulation switch usually fixes it without abandoning topical delivery entirely.
Urinary Changes: The BPH Connection
This one is short but worth knowing. Topical testosterone can worsen the symptoms of existing benign prostatic hyperplasia (BPH, non-cancerous prostate enlargement that’s extremely common with age): more frequent urination, urgency, or difficulty starting urination.
TRT does not cause this condition. It can amplify a problem that’s already there. If you had diagnosed BPH before starting, that history should be documented with your clinic, and you should monitor urinary symptoms specifically during the first 8–12 weeks. If symptoms escalate noticeably, that’s a clinic conversation, not a reason to silently stop.
Testosterone Format and Brand Differences That Actually Matter
You don’t need a brand-by-brand encyclopedia. You need the clinically relevant differences:
| Format | Key practical difference | Specific concern |
| Gel 1% (AndroGel, Testim) | Larger application volume, higher alcohol content | Skin dryness, higher transfer volume |
| Gel 1.62% (AndroGel 1.62, Fortesta) | Smaller volume, same alcohol issue | Easier to apply, similar irritation profile |
| Cream (compounded) | Oil base, lower alcohol | Less irritation, but longer transfer window, cover the site |
| Spray (Axiron) | Underarm application, pump dosing | Dosing accuracy, armpit irritation |
| Patch (Androderm) | Continuous delivery, no transference risk | Skin reactions at the patch site, adhesion issues |
If you’re getting skin reactions on one format, switching to a lower-alcohol or oil-based formulation is worth trying before abandoning topical delivery entirely. Note the cream tradeoff, lower irritation but a longer window during which it can transfer, so covering the site matters more, not less.
What Your Clinic Should Be Doing, and What to Ask If They’re Not
Gel-specific standard of care that’s frequently skipped:
- Testosterone levels tested 2–4 hours after application, not at random times. Gel absorption timing significantly affects results, a random draw can read falsely low or high.
- If levels are below target at 8 weeks on standard dosing, scrotal application should be discussed before simply escalating dose. It’s often the more effective lever for poor absorbers.
- Transference guidance should be a specific protocol, timing, covering, washing, not the vague “avoid skin contact” instruction.
- BPH history should be documented before prescribing, not discovered after urinary symptoms appear.
If your clinic is doing none of these, that’s worth raising directly, or treating as a reason for a second opinion.
The Bottom Line
Gel is the right delivery method if four things are true: daily application fits your routine, you don’t have young children with unavoidable close skin contact, your partner is not pregnant, and your skin absorbs it adequately.
If the first three are true but absorption is poor, the answer isn’t necessarily abandoning gel, scrotal application is worth trying before switching to injections. If any of the first three aren’t true, the conversation with your clinic is about switching delivery method entirely, not switching brands.
That distinction is exactly where a proper clinical review earns its keep. If you have a pregnant partner or young children and you’re unsure whether gel is appropriate for your household, or your levels aren’t reaching target despite doing everything right, that’s not something to resolve by guessing. Action TRT reviews application protocol, absorption, and household risk together, so the decision to stay on gel, change the protocol, or switch methods is made on the specifics of your situation rather than a generic warning label.
